Learn About the Injection Experience for Ulcerative Colitis | SIMPONI® (golimumab)

For adults with moderately to severely active ulcerative colitis (UC) who are corticosteroid dependent or have failed or were intolerant to conventional therapy

SIMPONI® offers an injection experience to consider for your patients1,2

Nearly half the injections compared with Humira® (per first year of treatment)1,2

SIMPONI® is administered by subcutaneous (SC) injection. The induction dosage regimen is 200 mg at Week 0, followed by 100 mg at Week 2, and then 100 mg maintenance therapy every 4 weeks.

Humira® is administered by SC injection. The induction dosage regimen is 160 mg at Week 0, followed by 80 mg at Week 2, and then 2 weeks later begin a maintenance dose of 40 mg every other week.

This is not intended to compare the safety, effectiveness, or uses of these treatments. Please refer to each product’s Prescribing Information for recommended dosing and administration. Humira® is a registered trademark of AbbVie Inc.

 

*Number of Humira® induction injections calculated using a 80-mg/0.8-mL single-use prefilled pen.

The SmartJect® autoinjector: designed to keep the needle out of sight

Autoinjector Features
Autoinjector Features

Patients will hear a first click when the dose begins to dispense and a second click when the injection is complete and the needle has retracted.

SIMPONI® is intended for use under the guidance and supervision of a physician. Patients may self-inject SIMPONI® after physician approval and proper training.

Prior to initiating SIMPONI®, and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection. Prior to initiating SIMPONI®, patients should be tested for hepatitis B viral infection.

Injection-site reactions

In the PURSUIT Induction study,

of SIMPONI®-treated patients (n=25/734) reported injection-site reactions vs 1.5% of placebo patients (n=5/330). Injection-site reactions included redness, swelling, itching, pain, bruising, and tingling.1,3Most common adverse reactions are upper respiratory tract infection, nasopharyngitis, and injection-site reactions.

References: 1. SIMPONI® (golimumab) Prescribing Information. Janssen Biotech, Inc. 2. HUMIRA® (adalimumab) Prescribing Information. AbbVie Inc. 3. Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95.